Related references
Note: Only part of the references are listed.The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019
Hye-Na Kang et al.
BIOLOGICALS (2020)
Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial
Marie-Christine Bielsky et al.
DRUG DISCOVERY TODAY (2020)
Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment
Jae Hee Lee et al.
BIODRUGS (2019)
The first World Health Organization International Standard for infliximab products: A step towards maintaining harmonized biological activity
Clive Metcalfe et al.
MABS (2019)
International standards for monoclonal antibodies to support pre- and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximab
Sandra Prior et al.
MABS (2018)
Maintaining consistent quality and clinical performance of biopharmaceuticals
William C. Lamanna et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
Biopharmaceutical benchmarks 2018
Gary Walsh
NATURE BIOTECHNOLOGY (2018)
Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar
Seokkyun Kim et al.
MABS (2017)
Biosimilars: Key regulatory considerations and similarity assessment tools
Carol F. Kirchhoff et al.
BIOTECHNOLOGY AND BIOENGINEERING (2017)
Translating European regulatory approval into healthcare uptake for biosimilars: the second translational gap
Virginia Acha et al.
TECHNOLOGY ANALYSIS & STRATEGIC MANAGEMENT (2017)
Monoclonal antibody biosimilars
Natasha Udpa et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents
Balazs Vezer et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
The role of the quality assessment in the determination of overall biosimilarity: A simulated case study exercise
Martin Schiestl et al.
BIOLOGICALS (2014)
Biosimilars in rheumatology: the wind of change
Christian K. Schneider
ANNALS OF THE RHEUMATIC DISEASES (2013)
Setting the stage for biosimilar monoclonal antibodies
Christian K. Schneider et al.
NATURE BIOTECHNOLOGY (2012)
Intended use of Reference Products & WHO International Standards/Reference Reagents in the development of Similar Biological Products (Biosimilars)
Robin Thorpe et al.
BIOLOGICALS (2011)
Acceptable changes in quality attributes of glycosylated biopharmaceuticals
Martin Schiestl et al.
NATURE BIOTECHNOLOGY (2011)
Toward biosimilar monoclonal antibodies
Christian K. Schneider et al.
NATURE BIOTECHNOLOGY (2008)
Share Paper
